Skip to main content
. 2013 Feb;2(1):14–22. doi: 10.3978/j.issn.2218-6751.2012.11.05

Table 2. Clinical data with figitumumab.

          Primary endpoint P value
Phase II (8)
    Carboplatin/paclitaxel/figitumumab          ORR 54%      P<0.0001 (95% CI, 0.44 to 0.64)
    Carboplatin/paclitaxel          ORR 42%
Phase III (9)
    Carboplatin/paclitaxel/figitumumab          OS 10.3 months      HR 1.23 (95% CI, 1.0-1.5), P=0.051
    Carboplatin/paclitaxel          OS 8.5 months
Phase III (not published)
    Figitumumab/erlotinib          OS: terminated for futility      n/a